메뉴 건너뛰기




Volumn 17, Issue 3, 2016, Pages 381-394

Drugs for the treatment of peripheral neuropathies

Author keywords

Amyloidosis; Chemotherapy; Diabetes; Inflammation; Peripheral neuropathy; Therapy

Indexed keywords

ACTOVEGIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; SMALL INTERFERING RNA; STEROID; TAFAMIDIS; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT;

EID: 84957941304     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1120719     Document Type: Review
Times cited : (14)

References (101)
  • 1
    • 0029431672 scopus 로고
    • Chronic symmetric symptomatic polyneuropathy in the elderly: A field screening investigation in two Italian regions I. Prevalence and general characteristics of the sample
    • Italian General Practitioner Study Group (IGPSG).
    • Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995;45(10):1832-1836.
    • (1995) Neurology , vol.45 , Issue.10 , pp. 1832-1836
  • 2
    • 84907416004 scopus 로고    scopus 로고
    • Recent advances in transthyretin amyloidosis therapy
    • Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
    • (2014) Transl Neurodegener , vol.3 , pp. 19
    • Ueda, M.1    Ando, Y.2
  • 3
    • 22844447647 scopus 로고    scopus 로고
    • Transthyretin-related familial amyloidotic polyneuropathy
    • Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057-1062.
    • (2005) Arch Neurol , vol.62 , Issue.7 , pp. 1057-1062
    • Ando, Y.1    Nakamura, M.2    Araki, S.3
  • 5
    • 0030004644 scopus 로고    scopus 로고
    • The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid
    • Lai Z, Colón W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996;35(20):6470-6482.
    • (1996) Biochemistry , vol.35 , Issue.20 , pp. 6470-6482
    • Lai, Z.1    Colón, W.2    Kelly, J.W.3
  • 6
    • 84914125201 scopus 로고    scopus 로고
    • Current and future treatment of amyloid neuropathies
    • Adams D, Cauquil C, Theaudin M, et al. Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014;14(12):1437-1451.
    • (2014) Expert Rev Neurother , vol.14 , Issue.12 , pp. 1437-1451
    • Adams, D.1    Cauquil, C.2    Theaudin, M.3
  • 7
    • 0029431672 scopus 로고
    • Chronic symmetric symptomatic polyneuropathy in the elderly: A field screening investigation in two Italian regions I. Prevalence and general characteristics of the sample
    • Italian General Practitioner Study Group (IGPSG)
    • Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995;45(10):1832-1836.
    • (1995) Neurology , vol.45 , Issue.10 , pp. 1832-1836
  • 8
    • 84907416004 scopus 로고    scopus 로고
    • Recent advances in transthyretin amyloidosis therapy
    • Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
    • (2014) Transl Neurodegener , vol.3 , pp. 19
    • Ueda, M.1    Ando, Y.2
  • 9
    • 22844447647 scopus 로고    scopus 로고
    • Transthyretin-related familial amyloidotic polyneuropathy
    • Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057-1062.
    • (2005) Arch Neurol , vol.62 , Issue.7 , pp. 1057-1062
    • Ando, Y.1    Nakamura, M.2    Araki, S.3
  • 11
    • 0030004644 scopus 로고    scopus 로고
    • The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid
    • Lai Z, Colón W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996;35(20):6470-6482.
    • (1996) Biochemistry , vol.35 , Issue.20 , pp. 6470-6482
    • Lai, Z.1    Colón, W.2    Kelly, J.W.3
  • 12
    • 84914125201 scopus 로고    scopus 로고
    • Current and future treatment of amyloid neuropathies
    • Adams D, Cauquil C, Theaudin M, et al. Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014;14(12):1437-1451.
    • (2014) Expert Rev Neurother , vol.14 , Issue.12 , pp. 1437-1451
    • Adams, D.1    Cauquil, C.2    Theaudin, M.3
  • 13
    • 84873979913 scopus 로고    scopus 로고
    • Guideline of transthyretin-related hereditary amyloidosis for clinicians
    • Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
    • (2013) Orphanet J Rare Dis , vol.8 , pp. 31
    • Ando, Y.1    Coelho, T.2    Berk, J.L.3
  • 14
    • 6944240027 scopus 로고    scopus 로고
    • Liver transplantation in transthyretin-related familial amyloid polyneuropathy
    • Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004;17(5):615-620.
    • (2004) Curr Opin Neurol , vol.17 , Issue.5 , pp. 615-620
    • Stangou, A.J.1    Hawkins, P.N.2
  • 15
    • 79959936896 scopus 로고    scopus 로고
    • Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR)
    • Wilczek HE, Larsson M, Ericzon BG, et al. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193-195.
    • (2011) Amyloid , vol.18 , pp. 193-195
    • Wilczek, H.E.1    Larsson, M.2    Ericzon, B.G.3
  • 16
    • 84861451481 scopus 로고    scopus 로고
    • Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy
    • Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012;19 (Suppl 1):43-44.
    • (2012) Amyloid , vol.19 , pp. 43-44
    • Ackermann, E.J.1    Guo, S.2    Booten, S.3
  • 17
    • 84889238225 scopus 로고    scopus 로고
    • Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
    • Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802-2814.
    • (2013) J Neurol , vol.260 , Issue.11 , pp. 2802-2814
    • Coelho, T.1    Maia, L.F.2    Da Silva, A.M.3
  • 18
    • 84862222705 scopus 로고    scopus 로고
    • Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
    • Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-792.
    • (2012) Neurology , vol.79 , Issue.8 , pp. 785-792
    • Coelho, T.1    Maia, L.F.2    Martins Da Silva, A.3
  • 19
    • 84887402882 scopus 로고    scopus 로고
    • Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy
    • Lozeron P, Théaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539-1545.
    • (2013) Eur J Neurol , vol.20 , Issue.12 , pp. 1539-1545
    • Lozeron, P.1    Théaudin, M.2    Mincheva, Z.3
  • 20
    • 84890488396 scopus 로고    scopus 로고
    • Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
    • Merlini G, Planté-Bordeneuve V, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011-1020.
    • (2013) J Cardiovasc Transl Res , vol.6 , Issue.6 , pp. 1011-1020
    • Merlini, G.1    Planté-Bordeneuve, V.2
  • 21
    • 84890954073 scopus 로고    scopus 로고
    • Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial
    • Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658-2667.
    • (2013) JAMA , vol.310 , Issue.24 , pp. 2658-2667
    • Berk, J.L.1    Suhr, O.B.2    Obici, L.3
  • 22
    • 33646244247 scopus 로고    scopus 로고
    • Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
    • Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33 (5):609-618.
    • (2006) Muscle Nerve , vol.33 , Issue.5 , pp. 609-618
    • Benson, M.D.1    Kluve-Beckerman, B.2    Zeldenrust, S.R.3
  • 23
    • 84883118140 scopus 로고    scopus 로고
    • Safety and efficacy of RNAi therapy for transthyretin amyloidosis
    • Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819-829.
    • (2013) N Engl J Med , vol.369 , Issue.9 , pp. 819-829
    • Coelho, T.1    Adams, D.2    Silva, A.3
  • 24
    • 78149282151 scopus 로고    scopus 로고
    • Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
    • Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93-97.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 93-97
    • Bodin, K.1    Ellmerich, S.2    Kahan, M.C.3
  • 25
    • 0031034253 scopus 로고    scopus 로고
    • Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome
    • Hughes R, Swan A, Cornblath D, et al. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225-230.
    • (1997) Lancet , vol.349 , Issue.9047 , pp. 225-230
    • Hughes, R.1    Swan, A.2    Cornblath, D.3
  • 27
    • 84923049034 scopus 로고    scopus 로고
    • Optimizing IgG therapy in chronic autoimmune neuropathies: A hypothesis driven approach
    • Berger M, Allen JA. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve. 2015;51(3):315-326.
    • (2015) Muscle Nerve , vol.51 , Issue.3 , pp. 315-326
    • Berger, M.1    Allen, J.A.2
  • 29
    • 44949251941 scopus 로고    scopus 로고
    • Eculizumab prevents anti-ganglioside antibodymediated neuropathy in a murine model
    • Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibodymediated neuropathy in a murine model. Brain. 2008;131(Pt 5):1197-1208.
    • (2008) Brain , vol.131 , pp. 1197-1208
    • Halstead, S.K.1    Zitman, F.M.2    Humphreys, P.D.3
  • 30
    • 84930199161 scopus 로고    scopus 로고
    • Treatment of chronic inflammatory demyelinating polyneuropathy
    • Kleyman I, Brannagan TH. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep. 2015;15(7):47.
    • (2015) Curr Neurol Neurosci Rep , vol.15 , Issue.7 , pp. 47
    • Kleyman, I.1    Brannagan, T.H.2
  • 31
    • 16544372731 scopus 로고    scopus 로고
    • Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
    • Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;8: CD003906.
    • (2015) Cochrane Database Syst Rev , vol.8 , pp. CD003906
    • Mehndiratta, M.M.1    Hughes, R.A.2    Pritchard, J.3
  • 32
    • 77649176429 scopus 로고    scopus 로고
    • European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision
    • Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol. 2010;17(3):356-363.
    • (2010) Eur J Neurol , vol.17 , Issue.3 , pp. 356-363
    • Van Den Bergh, P.Y.1    Hadden, R.D.2    Bouche, P.3
  • 33
    • 70249146129 scopus 로고    scopus 로고
    • Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
    • Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009;1:CD001797.
    • (2009) Cochrane Database Syst Rev , vol.1 , pp. CD001797
    • Eftimov, F.1    Winer, J.B.2    Vermeulen, M.3
  • 34
    • 84861189500 scopus 로고    scopus 로고
    • Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial
    • Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493-502.
    • (2012) Lancet Neurol , vol.11 , Issue.6 , pp. 493-502
    • Nobile-Orazio, E.1    Cocito, D.2    Jann, S.3
  • 35
    • 0019463420 scopus 로고
    • High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
    • Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228-1231.
    • (1981) Lancet , vol.1 , Issue.8232 , pp. 1228-1231
    • Imbach, P.1    Barandun, S.2    D'Apuzzo, V.3
  • 36
    • 79954600098 scopus 로고    scopus 로고
    • Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
    • Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133-141.
    • (2011) Clin Immunol , vol.139 , Issue.2 , pp. 133-141
    • Berger, M.1    Rojavin, M.2    Kiessling, P.3
  • 37
    • 84879200850 scopus 로고    scopus 로고
    • Bioavailability of IgG administered by the subcutaneous route
    • Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33(5):984-990.
    • (2013) J Clin Immunol , vol.33 , Issue.5 , pp. 984-990
    • Berger, M.1    Jolles, S.2    Orange, J.S.3
  • 38
    • 85011864681 scopus 로고    scopus 로고
    • Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
    • Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;1:CD002062.
    • (2015) Cochrane Database Syst Rev , vol.1 , pp. CD002062
    • Hughes, R.A.1    Mehndiratta, M.M.2
  • 39
    • 84939251115 scopus 로고    scopus 로고
    • Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP
    • Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729-734.
    • (2015) J Neurol Neurosurg Psychiatry , vol.86 , Issue.7 , pp. 729-734
    • Nobile-Orazio, E.1    Cocito, D.2    Jann, S.3
  • 40
    • 84940788734 scopus 로고    scopus 로고
    • A retrospective study on the efficacy and safety of intraveinous immunoglobulin (Tegeline()) in patients with chronic inflammatory demyelinating polyneuropathy
    • Robert F, Edan G, Nicolas G, et al. A retrospective study on the efficacy and safety of intraveinous immunoglobulin (Tegeline()) in patients with chronic inflammatory demyelinating polyneuropathy. Presse Med. 2015;44(7-8):e291-e300.
    • (2015) Presse Med , vol.44 , Issue.7-8 , pp. e291-e300
    • Robert, F.1    Edan, G.2    Nicolas, G.3
  • 41
    • 74549226510 scopus 로고    scopus 로고
    • A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy
    • Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289-294.
    • (2010) Eur J Neurol , vol.17 , Issue.2 , pp. 289-294
    • Cocito, D.1    Paolasso, I.2    Antonini, G.3
  • 42
    • 84905164148 scopus 로고    scopus 로고
    • Treatment of multifocal motor neuropathy with intravenous immunoglobulin
    • Koski CL. Treatment of multifocal motor neuropathy with intravenous immunoglobulin. J Clin Immunol. 2014;34 (Suppl 1):S127-S131.
    • (2014) J Clin Immunol , vol.34 , pp. S127-S131
    • Koski, C.L.1
  • 43
    • 84921031301 scopus 로고    scopus 로고
    • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: Improved tolerability and patient satisfaction
    • Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14-19.
    • (2015) Ther Adv Neurol Disord , vol.8 , Issue.1 , pp. 14-19
    • Hadden, R.D.1    Marreno, F.2
  • 44
    • 84932142511 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders
    • Yoon MS, Gold R, Kerasnoudis A. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord. 2015;8(4):153-159.
    • (2015) Ther Adv Neurol Disord , vol.8 , Issue.4 , pp. 153-159
    • Yoon, M.S.1    Gold, R.2    Kerasnoudis, A.3
  • 45
    • 33746454655 scopus 로고    scopus 로고
    • European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy
    • van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol. 2006;13(8):802-808.
    • (2006) Eur J Neurol , vol.13 , Issue.8 , pp. 802-808
    • Van Schaik, I.N.1    Bouche, P.2    Illa, I.3
  • 46
    • 0027417176 scopus 로고
    • Multifocal motor neuropathy: Response to human immune globulin
    • Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33(3):237-242.
    • (1993) Ann Neurol , vol.33 , Issue.3 , pp. 237-242
    • Chaudhry, V.1    Corse, A.M.2    Cornblath, D.R.3
  • 47
  • 48
    • 0034659131 scopus 로고    scopus 로고
    • Anti-sulfatide IgM antibodies in peripheral neuropathy
    • Carpo M, Meucci N, Allaria S, et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci. 2000;176(2):144-150.
    • (2000) J Neurol Sci , vol.176 , Issue.2 , pp. 144-150
    • Carpo, M.1    Meucci, N.2    Allaria, S.3
  • 49
    • 0023927923 scopus 로고
    • Treatment of patients with neuropathy and anti-MAG IgM M-proteins
    • Nobile-Orazio E, Baldini L, Barbieri S, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988;24(1):93-97.
    • (1988) Ann Neurol , vol.24 , Issue.1 , pp. 93-97
    • Nobile-Orazio, E.1    Baldini, L.2    Barbieri, S.3
  • 50
    • 0028102447 scopus 로고
    • Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy
    • Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36(3):416-424.
    • (1994) Ann Neurol , vol.36 , Issue.3 , pp. 416-424
    • Nobile-Orazio, E.1    Manfredini, E.2    Carpo, M.3
  • 51
    • 84864526040 scopus 로고    scopus 로고
    • Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies
    • Lunn MP, Nobile-Orazio E. Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2012;5:CD002827.
    • (2012) Cochrane Database Syst Rev , vol.5 , pp. CD002827
    • Lunn, M.P.1    Nobile-Orazio, E.2
  • 52
    • 84942198795 scopus 로고    scopus 로고
    • POEMS syndrome: Update on diagnosis, risk-stratification, and management
    • Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90(10):951-962.
    • (2015) Am J Hematol , vol.90 , Issue.10 , pp. 951-962
    • Dispenzieri, A.1
  • 53
    • 84876174288 scopus 로고    scopus 로고
    • New advances in the diagnosis and treatment of POEMS syndrome
    • Li J, Zhou DB. New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol. 2013;161 (3):303-315.
    • (2013) Br J Haematol , vol.161 , Issue.3 , pp. 303-315
    • Li, J.1    Zhou, D.B.2
  • 54
    • 84873049728 scopus 로고    scopus 로고
    • Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome
    • Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6:CD006828.
    • (2012) Cochrane Database Syst Rev , vol.6 , pp. CD006828
    • Kuwabara, S.1    Dispenzieri, A.2    Arimura, K.3
  • 56
    • 0041308236 scopus 로고    scopus 로고
    • Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology
    • Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491-494.
    • (2003) Diabetes Care , vol.26 , Issue.2 , pp. 491-494
    • Moulik, P.K.1    Mtonga, R.2    Gill, G.V.3
  • 57
    • 20144389536 scopus 로고    scopus 로고
    • Diabetic neuropathies: A statement by the American Diabetes Association
    • Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-962.
    • (2005) Diabetes Care , vol.28 , Issue.4 , pp. 956-962
    • Boulton, A.J.1    Vinik, A.I.2    Arezzo, J.C.3
  • 58
    • 84860818001 scopus 로고    scopus 로고
    • Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K
    • Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220-2224.
    • (2011) Diabetes Care , vol.34 , Issue.10 , pp. 2220-2224
    • Abbott, C.A.1    Malik, R.A.2    Van Ross, E.R.3
  • 59
    • 62349139024 scopus 로고    scopus 로고
    • Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: The MONICA/KORA Augsburg Surveys S2 and S3
    • Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393-400.
    • (2009) Pain Med , vol.10 , Issue.2 , pp. 393-400
    • Ziegler, D.1    Rathmann, W.2    Dickhaus, T.3
  • 60
    • 0029994187 scopus 로고    scopus 로고
    • Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study
    • Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia. 1996;39(11):1377-1384.
    • (1996) Diabetologia , vol.39 , Issue.11 , pp. 1377-1384
    • Tesfaye, S.1    Stevens, L.K.2    Stephenson, J.M.3
  • 62
    • 84969413170 scopus 로고    scopus 로고
    • http://www.who.int/diabetes/facts/world-figures
  • 63
    • 84861111124 scopus 로고    scopus 로고
    • Diabetic neuropathy: Clinical manifestations and current treatments
    • Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-534.
    • (2012) Lancet Neurol , vol.11 , Issue.6 , pp. 521-534
    • Callaghan, B.C.1    Cheng, H.T.2    Stables, C.L.3
  • 64
    • 84902708889 scopus 로고    scopus 로고
    • Diabetic neuropathy: Mechanisms, emerging treatments, and subtypes
    • Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473.
    • (2014) Curr Neurol Neurosci Rep , vol.14 , Issue.8 , pp. 473
    • Albers, J.W.1    Pop-Busui, R.2
  • 65
    • 84929353718 scopus 로고    scopus 로고
    • Critical appraisal of international guidelines for the management of diabetic neuropathy: Is there global agreement in the internet era?
    • Sun M, Zhang M, Shen J, et al. Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era? Int J Endocrinol. 2015;2015:519032.
    • (2015) Int J Endocrinol , vol.2015 , pp. 519032
    • Sun, M.1    Zhang, M.2    Shen, J.3
  • 66
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial Research Group
    • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
    • (1993) N Engl J Med , vol.329 , Issue.14 , pp. 977-986
  • 67
    • 84866324862 scopus 로고    scopus 로고
    • Enhanced glucose control for preventing and treating diabetic neuropathy
    • Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.
    • (2012) Cochrane Database Syst Rev , vol.6 , pp. CD007543
    • Callaghan, B.C.1    Little, A.A.2    Feldman, E.L.3
  • 68
    • 84901212150 scopus 로고    scopus 로고
    • Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
    • Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2: CD009122.
    • (2014) Cochrane Database Syst Rev , vol.2 , pp. CD009122
    • Fullerton, B.1    Jeitler, K.2    Seitz, M.3
  • 69
    • 79960959816 scopus 로고    scopus 로고
    • Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials
    • Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
    • (2011) BMJ , vol.343 , pp. d4169
    • Boussageon, R.1    Bejan-Angoulvant, T.2    Saadatian-Elahi, M.3
  • 70
    • 84893708965 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy
    • Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167-184.
    • (2014) Pain Pract , vol.14 , Issue.2 , pp. 167-184
    • Snedecor, S.J.1    Sudharshan, L.2    Cappelleri, J.C.3
  • 71
    • 84879967614 scopus 로고    scopus 로고
    • Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: A randomised controlled trial
    • Pop-Busui R, Stevens MJ, Raffel DM, et al. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia. 2013;56(8):1835-1844.
    • (2013) Diabetologia , vol.56 , Issue.8 , pp. 1835-1844
    • Pop-Busui, R.1    Stevens, M.J.2    Raffel, D.M.3
  • 72
    • 84910627065 scopus 로고    scopus 로고
    • Efficacy of ?-lipoic acid in diabetic neuropathy
    • Papanas N, Ziegler D. Efficacy of ?-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15 (18):2721-2731.
    • (2014) Expert Opin Pharmacother , vol.15 , Issue.18 , pp. 2721-2731
    • Papanas, N.1    Ziegler, D.2
  • 73
    • 68149106189 scopus 로고    scopus 로고
    • Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
    • Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-1484.
    • (2009) Diabetes Care , vol.32 , Issue.8 , pp. 1479-1484
    • Ziegler, D.1    Movsesyan, L.2    Mankovsky, B.3
  • 74
    • 33846075220 scopus 로고    scopus 로고
    • C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
    • Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71-76.
    • (2007) Diabetes Care , vol.30 , Issue.1 , pp. 71-76
    • Ekberg, K.1    Brismar, T.2    Johansson, B.L.3
  • 75
    • 42449127541 scopus 로고    scopus 로고
    • Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes
    • Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res. 2008;2008:457912.
    • (2008) Exp Diabetes Res , vol.2008 , pp. 457912
    • Ekberg, K.1    Johansson, B.L.2
  • 76
    • 83155180436 scopus 로고    scopus 로고
    • Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: The delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial
    • Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58(5):776-783.
    • (2011) Hypertension , vol.58 , Issue.5 , pp. 776-783
    • Ruggenenti, P.1    Lauria, G.2    Iliev, I.P.3
  • 77
    • 77953823105 scopus 로고    scopus 로고
    • EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
    • Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
    • (2010) Eur J Neurol , vol.17 , Issue.9 , pp. e1113-e1188
    • Attal, N.1    Cruccu, G.2    Baron, R.3
  • 78
    • 58649121268 scopus 로고    scopus 로고
    • Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: Discrepancies between direct and indirect meta-analyses of randomized controlled trials
    • Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009;24(2):178-188.
    • (2009) J Gen Intern Med , vol.24 , Issue.2 , pp. 178-188
    • Chou, R.1    Carson, S.2    Chan, B.K.3
  • 80
    • 79957500607 scopus 로고    scopus 로고
    • Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation
    • Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-1765.
    • (2011) Neurology , vol.76 , Issue.20 , pp. 1758-1765
    • Bril, V.1    England, J.2    Franklin, G.M.3
  • 81
    • 84868008289 scopus 로고    scopus 로고
    • Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention
    • Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(SUPPL.4):iv45-iv54.
    • (2012) Neuro-Oncology , vol.14 , pp. iv45-iv54
    • Grisold, W.1    Cavaletti, G.2    Windebank, A.J.3
  • 82
    • 84905454673 scopus 로고    scopus 로고
    • Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline
    • Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-1967.
    • (2014) J Clin Oncol , vol.32 , Issue.18 , pp. 1941-1967
    • Hershman, D.L.1    Lacchetti, C.2    Dworkin, R.H.3
  • 83
    • 84907424832 scopus 로고    scopus 로고
    • Interventions for preventing neuropathy caused by cisplatin and related compounds
    • Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
    • (2014) Cochrane Database Syst Rev , vol.3 , pp. CD005228
    • Albers, J.W.1    Chaudhry, V.2    Cavaletti, G.3
  • 84
    • 79953012566 scopus 로고    scopus 로고
    • Interventions for preventing neuropathy caused by cisplatin and related compounds
    • Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011;2: CD005228.
    • (2011) Cochrane Database Syst Rev , vol.2 , pp. CD005228
    • Albers, J.W.1    Chaudhry, V.2    Cavaletti, G.3
  • 85
    • 39049123158 scopus 로고    scopus 로고
    • Interventions for preventing neuropathy caused by cisplatin and related compounds
    • Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007;1: CD005228.
    • (2007) Cochrane Database Syst Rev , vol.1 , pp. CD005228
    • Albers, J.1    Chaudhry, V.2    Cavaletti, G.3
  • 86
    • 84945452920 scopus 로고    scopus 로고
    • Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy
    • Ben-Arye E, Samuels N, Schiff E, et al. Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy. Support Care Cancer. 2015;23(12):3411-3419.
    • (2015) Support Care Cancer , vol.23 , Issue.12 , pp. 3411-3419
    • Ben-Arye, E.1    Samuels, N.2    Schiff, E.3
  • 87
    • 84931087350 scopus 로고    scopus 로고
    • Treatment-related symptom management in patients with multiple myeloma: A review
    • Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer. 2015;23(5):1431-1445.
    • (2015) Support Care Cancer , vol.23 , Issue.5 , pp. 1431-1445
    • Colson, K.1
  • 88
    • 84928810867 scopus 로고    scopus 로고
    • Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives
    • Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54(5):587-591.
    • (2015) Acta Oncol , vol.54 , Issue.5 , pp. 587-591
    • Ewertz, M.1    Qvortrup, C.2    Eckhoff, L.3
  • 89
    • 84939262907 scopus 로고    scopus 로고
    • Chemotherapyinduced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry
    • Mols F, Beijers AJ, Vreugdenhil G, et al. Chemotherapyinduced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv. 2015;9(3):512-522.
    • (2015) J Cancer Surviv , vol.9 , Issue.3 , pp. 512-522
    • Mols, F.1    Beijers, A.J.2    Vreugdenhil, G.3
  • 90
    • 78649906324 scopus 로고    scopus 로고
    • Chemotherapy-induced peripheral neurotoxicity
    • Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657-666.
    • (2010) Nat Rev Neurol , vol.6 , Issue.12 , pp. 657-666
    • Cavaletti, G.1    Marmiroli, P.2
  • 91
    • 84858799716 scopus 로고    scopus 로고
    • Chemotherapyinduced peripheral neurotoxicity (CIPN): An update
    • Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapyinduced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51-77.
    • (2012) Crit Rev Oncol Hematol , vol.82 , Issue.1 , pp. 51-77
    • Argyriou, A.A.1    Bruna, J.2    Marmiroli, P.3
  • 92
    • 0345060438 scopus 로고    scopus 로고
    • Paclitaxel and cisplatin-induced neurotoxicity: A protective role of acetyl-L-carnitine
    • Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res. 2003;9(15):5756-5767.
    • (2003) Clin Cancer Res , vol.9 , Issue.15 , pp. 5756-5767
    • Pisano, C.1    Pratesi, G.2    Laccabue, D.3
  • 93
    • 84927610343 scopus 로고    scopus 로고
    • Platinum-induced neurotoxicity and preventive strategies: Past, present, and future
    • Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20(4):411-432.
    • (2015) Oncologist , vol.20 , Issue.4 , pp. 411-432
    • Avan, A.1    Postma, T.J.2    Ceresa, C.3
  • 94
    • 52949143529 scopus 로고    scopus 로고
    • Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy
    • Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann Pharmacother. 2008;42(10):1481-1485.
    • (2008) Ann Pharmacother , vol.42 , Issue.10 , pp. 1481-1485
    • Amara, S.1
  • 96
    • 84919361240 scopus 로고    scopus 로고
    • Chemotherapyinduced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models
    • Carozzi VA, Chiorazzi A, Canta A, et al. Chemotherapyinduced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal models. Exp Neurol. 2015;264:92-102.
    • (2015) Exp Neurol , vol.264 , pp. 92-102
    • Carozzi, V.A.1    Chiorazzi, A.2    Canta, A.3
  • 97
    • 84870851045 scopus 로고    scopus 로고
    • The fundamental role of morphology in experimental neurotoxicology: The example of chemotherapy-induced peripheral neurotoxicity
    • Marmiroli P, Nicolini G, Miloso M, et al. The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. Ital J Anat Embryol. 2012;117(2):75-97.
    • (2012) Ital J Anat Embryol , vol.117 , Issue.2 , pp. 75-97
    • Marmiroli, P.1    Nicolini, G.2    Miloso, M.3
  • 98
    • 42649115088 scopus 로고    scopus 로고
    • Neurotoxic effects of antineoplastic drugs: The lesson of pre-clinical studies
    • Cavaletti G, Nicolini G, Marmiroli P. Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci. 2008;13:3506-3524.
    • (2008) Front Biosci , vol.13 , pp. 3506-3524
    • Cavaletti, G.1    Nicolini, G.2    Marmiroli, P.3
  • 99
    • 0033675496 scopus 로고    scopus 로고
    • Lipid-free versus lipid-bound P2 protein-induced experimental allergic neuritis: Clinicopathological, neurophysiological, and immunological study
    • Cavaletti G, Matà S, Fasano A, et al. Lipid-free versus lipid-bound P2 protein-induced experimental allergic neuritis: clinicopathological, neurophysiological, and immunological study. J Neurosci Res. 2000;62(5): 709-716.
    • (2000) J Neurosci Res , vol.62 , Issue.5 , pp. 709-716
    • Cavaletti, G.1    Matà, S.2    Fasano, A.3
  • 100
    • 84878692548 scopus 로고    scopus 로고
    • Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study
    • Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013;21 (7):2059-2066.
    • (2013) Support Care Cancer , vol.21 , Issue.7 , pp. 2059-2066
    • Gewandter, J.S.1    Fan, L.2    Magnuson, A.3
  • 101
    • 0028035097 scopus 로고
    • Postural instability in patients with diabetic sensory neuropathy
    • Simoneau GG, Ulbrecht JS, Derr JA, et al. Postural instability in patients with diabetic sensory neuropathy. Diabetes Care. 1994;17(12):1411-1421.
    • (1994) Diabetes Care , vol.17 , Issue.12 , pp. 1411-1421
    • Simoneau, G.G.1    Ulbrecht, J.S.2    Derr, J.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.